Overview
* Certara ( CERT ) fiscal Q3 revenue grows 10% yr/yr, slightly missing analyst expectations
* Adjusted EPS for fiscal Q3 beats analyst expectations
* Net income for fiscal Q3 improved to $1.5 mln from a net loss last year
Outlook
* Certara ( CERT ) sees full-year 2025 revenue between $415 mln and $420 mln
* Company expects full-year adjusted EBITDA margin of approximately 32%
* Certara ( CERT ) anticipates full-year adjusted EPS of $0.45 to $0.47
Result Drivers
* SOFTWARE GROWTH - Driven by biosimulation software and M&A activities, software revenue increased by 22%
* SERVICE BOOKINGS DECLINE - Service bookings decreased by 9% due to softer trends among tier-one customers in Regulatory services
* BIOSIMULATION DEMAND - Strong demand for biosimulation solutions in software and QSP services, despite spending hesitancy in other service areas
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Slight $104.60 $104.90
Revenue Miss* mln mln (9
Analysts
)
Q3 Beat $0.14 $0.11 (9
Adjusted Analysts
EPS )
Q3 EPS $0.01
Q3 $22.20
Adjusted mln
Net
Income
Q3 Net $1.50
Income mln
Q3 $35.20
Adjusted mln
EBITDA
Q3 -$267,00
Pretax 0
Profit
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the software peer group is "buy"
* Wall Street's median 12-month price target for Certara Inc ( CERT ) is $16.00, about 27.7% above its November 5 closing price of $11.57
* The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 19 three months ago
Press Release:
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)